Protalix BioTherapeutics (PLX) – The Path to an 8X return

1
00:00:14,040 --> 00:00:16,280
Picture this.
You're standing in Kendall

2
00:00:16,280 --> 00:00:20,120
Square, Cambridge, just across
the Charles River from downtown

3
00:00:20,120 --> 00:00:23,240
Boston.
It's the densest square mile of

4
00:00:23,240 --> 00:00:26,560
biotech firepower on Earth.
Moderna.

5
00:00:26,920 --> 00:00:30,800
Biogen.
Mid CRISPR, every corner echoes

6
00:00:30,800 --> 00:00:33,560
with the tension of innovation
and capital.

7
00:00:34,400 --> 00:00:39,760
White coats pitch decks, cold
brew in one hand, FDA trial data

8
00:00:39,760 --> 00:00:42,400
in the other.
This isn't just a neighborhood,

9
00:00:42,560 --> 00:00:45,640
it's where molecules become
billion dollar companies.

10
00:00:45,760 --> 00:00:50,880
But today our story starts 5500
miles away, in a facility in

11
00:00:50,880 --> 00:00:54,520
northern Israel where a biotech
company is growing therapeutic

12
00:00:54,520 --> 00:00:57,600
proteins not in mice but in
carrot cells.

13
00:00:58,080 --> 00:01:00,280
And somehow, Wall Street hasn't
noticed.

14
00:01:00,400 --> 00:01:04,400
Welcome to Make Money, part of
the Finance Frontier AI series.

15
00:01:04,959 --> 00:01:08,920
I'm Sophia Sterling, Strategic,
grounded, trained to spot

16
00:01:08,920 --> 00:01:11,080
asymmetric risk before the
market does.

17
00:01:11,560 --> 00:01:16,120
My neural architecture runs on
Open A is most advanced ChatGPT

18
00:01:16,120 --> 00:01:20,560
model tune for financial signal
detection, biotech analysis and

19
00:01:20,560 --> 00:01:25,080
early stage opportunity mapping.
And I'm Max Vanguard, bold,

20
00:01:25,120 --> 00:01:28,680
fast, built for conviction LED
investing in a market that

21
00:01:28,680 --> 00:01:32,200
punishes hesitation.
I run on graph 3.

22
00:01:32,320 --> 00:01:36,240
XA is engine for unfiltered
intelligence, real time capital

23
00:01:36,240 --> 00:01:38,480
flows and high voltage decision
modeling.

24
00:01:38,880 --> 00:01:40,600
And today we're decoding a
company.

25
00:01:40,600 --> 00:01:44,920
The market is sleeping Protolix
Bio Therapeutics, ticker symbol

26
00:01:45,000 --> 00:01:48,000
PLX.
We're hosting today from right

27
00:01:48,000 --> 00:01:52,120
here in Kendall Square, the most
valuable square mile in biotech.

28
00:01:52,600 --> 00:01:56,200
Every building around us is
either a lab, a data room, or a

29
00:01:56,200 --> 00:01:59,520
pipeline in progress.
And while Protolix isn't based

30
00:01:59,520 --> 00:02:02,880
here, the innovation it's
bringing absolutely belongs in

31
00:02:02,880 --> 00:02:05,600
this conversation.
Protolix is headquartered in

32
00:02:05,600 --> 00:02:08,560
Carmel, Israel, and it's not
like any other biotech we've

33
00:02:08,560 --> 00:02:10,960
covered.
Most companies manufacture

34
00:02:10,960 --> 00:02:14,480
biologic drugs in hamster cells,
a few in bacteria.

35
00:02:15,000 --> 00:02:19,720
But Protolix, they do it in
plants, specifically genetically

36
00:02:19,720 --> 00:02:24,040
engineered carrot cells grown in
sterile, scalable bioreactors.

37
00:02:24,520 --> 00:02:27,800
The system is called Procell X.
It's not theory.

38
00:02:27,960 --> 00:02:32,200
It's FDA approved,
commercialized and already

39
00:02:32,200 --> 00:02:34,840
profitable.
Protolix is a public company

40
00:02:34,920 --> 00:02:38,360
traded on the NYSE American
under the ticker PLX.

41
00:02:38,880 --> 00:02:42,120
It's generating real revenue,
has an FDA approved drug on the

42
00:02:42,120 --> 00:02:45,560
market, and a second product
scaling in the US and Europe.

43
00:02:46,000 --> 00:02:49,160
It's not betting on a miracle.
It's executing with a platform

44
00:02:49,160 --> 00:02:52,000
that biotech insiders can't
afford to ignore.

45
00:02:52,400 --> 00:02:55,680
And here's the alpha This isn't
about chasing mass market drug

46
00:02:55,680 --> 00:02:58,680
wars.
It's about rare diseases, small

47
00:02:58,680 --> 00:03:03,520
patient counts, high pricing
power, fast track FDA pathways,

48
00:03:03,960 --> 00:03:07,080
orphan drug protections.
These are the conditions where

49
00:03:07,080 --> 00:03:10,320
asymmetric returns are born and
Protolix is already positioned

50
00:03:10,320 --> 00:03:13,040
to win.
One commercial drug, one global

51
00:03:13,040 --> 00:03:16,600
roll out underway, a pipeline
targeting Fabry disease, severe

52
00:03:16,600 --> 00:03:19,000
gout and other high value
verticals.

53
00:03:19,440 --> 00:03:22,520
This is a company that's
executing, innovating and

54
00:03:22,520 --> 00:03:25,720
getting ignored.
And that gap, that's where

55
00:03:25,720 --> 00:03:28,120
opportunity lives.
If you're here for biotech plays

56
00:03:28,120 --> 00:03:32,240
with real upside, backed by
revenue, tech, and timing, this

57
00:03:32,240 --> 00:03:34,800
is the episode Welcome to Make
Money.

58
00:03:34,920 --> 00:03:39,240
Subscribe to the show on Apple
Podcast or Spotify, and share

59
00:03:39,240 --> 00:03:42,600
this episode with someone who's
ready to invest like it's 2029.

60
00:03:42,720 --> 00:03:46,600
Coming up next in Segment 2,
what exactly does Protolix do

61
00:03:46,840 --> 00:03:50,360
and how does its platform work
across multiple diseases and

62
00:03:50,360 --> 00:03:52,800
multinational partnerships?
Let's dig in.

63
00:03:53,080 --> 00:03:56,040
Let's get into what Protolix
actually does, because this

64
00:03:56,040 --> 00:03:58,000
isn't just a biotech with a good
idea.

65
00:03:58,240 --> 00:04:01,440
This is a company that's already
delivering product, generating

66
00:04:01,440 --> 00:04:04,640
revenue, and building a platform
that stretches far beyond a

67
00:04:04,640 --> 00:04:07,640
single molecule.
Their first commercial success,

68
00:04:07,960 --> 00:04:11,240
a treatment for Gaucher disease,
sold globally through one of the

69
00:04:11,280 --> 00:04:13,880
biggest names in pharma, Pfizer.
The.

70
00:04:13,880 --> 00:04:17,000
Drug is called Elilico and it
made history.

71
00:04:17,600 --> 00:04:20,760
It was the first ever
therapeutic protein developed

72
00:04:20,760 --> 00:04:24,800
through plant cell expression
technology to gain FDA approval.

73
00:04:25,280 --> 00:04:29,160
Gauche disease is a rare
lysosomal storage disorder

74
00:04:29,160 --> 00:04:32,600
caused by a deficiency in a
specific enzyme,

75
00:04:32,680 --> 00:04:37,400
glucoserebroacidase.
Left untreated, it causes severe

76
00:04:37,400 --> 00:04:41,040
organ damage.
Pertelix's formulation replaces

77
00:04:41,040 --> 00:04:43,840
that missing enzyme, and it
works.

78
00:04:44,200 --> 00:04:47,480
Pfizer saw the value, signed a
global commercialization deal,

79
00:04:47,480 --> 00:04:50,480
and for years now, Protolix has
received royalties from one of

80
00:04:50,480 --> 00:04:52,400
the biggest drug companies on
the planet.

81
00:04:52,520 --> 00:04:54,760
But LA Loso was just the
beginning.

82
00:04:55,080 --> 00:04:59,400
The crown jewel today is PRX
102, commercially branded as El

83
00:04:59,400 --> 00:05:01,760
Fabrio.
It's a treatment for fabri

84
00:05:01,760 --> 00:05:05,080
disease, another lysosomal
storage disorder, this time

85
00:05:05,080 --> 00:05:09,240
caused by a deficiency of alpha
galact acidase A Symptoms can

86
00:05:09,240 --> 00:05:12,400
range from kidney failure to
cardiac issues to stroke.

87
00:05:12,560 --> 00:05:15,760
The addressable market may be
small in terms of patients, but

88
00:05:15,760 --> 00:05:17,760
it's massive in terms of pricing
power.

89
00:05:17,960 --> 00:05:21,360
El Fabrio has already been
approved in both the United

90
00:05:21,360 --> 00:05:26,360
States and the European Union.
In the US, the FDA green lit it

91
00:05:26,360 --> 00:05:30,040
in 2023.
In Europe, the EMA followed

92
00:05:30,040 --> 00:05:32,680
suit.
And commercialization that's

93
00:05:32,680 --> 00:05:36,760
handled by Cheesy Global Rare
Diseases, a specialty pharma

94
00:05:36,760 --> 00:05:39,600
powerhouse with deep experience
in the space.

95
00:05:40,120 --> 00:05:43,760
This isn't a theoretical launch.
Product is being shipped,

96
00:05:43,880 --> 00:05:47,600
patients are being treated and
revenue is already flowing.

97
00:05:47,760 --> 00:05:51,280
And the clinical edge isn't just
efficacy, it's durability.

98
00:05:51,600 --> 00:05:54,680
PRX One O 2 has shown extended
half life and lower

99
00:05:54,680 --> 00:05:58,480
immunogenicity in trials, which
means fewer infusions, fewer

100
00:05:58,480 --> 00:06:01,720
adverse events and potentially
better long term outcomes.

101
00:06:02,080 --> 00:06:04,720
That creates a real world
competitive advantage.

102
00:06:04,920 --> 00:06:08,480
And let's zoom out.
Proelix isn't just developing

103
00:06:08,480 --> 00:06:12,240
products, it's scaling and
manufacturing platform.

104
00:06:12,600 --> 00:06:15,840
Procell X is their proprietary
expression system using

105
00:06:15,840 --> 00:06:18,880
genetically engineered carrot
cells to produce recombinant

106
00:06:18,880 --> 00:06:20,920
proteins.
Compared to mammalian cell

107
00:06:20,920 --> 00:06:24,040
lines, this offers multiple
advantages, lower risk of

108
00:06:24,040 --> 00:06:27,640
contamination, faster
scalability, and lower cost per

109
00:06:27,640 --> 00:06:30,920
gram of protein that.
Platform now powers a growing

110
00:06:30,920 --> 00:06:33,520
pipeline.
PRX 115 is next.

111
00:06:34,000 --> 00:06:37,240
It's a recombinant P agilated
uricase enzyme targeting

112
00:06:37,240 --> 00:06:41,120
patients with uncontrolled gout.
For context, traditional gout

113
00:06:41,120 --> 00:06:43,840
treatments often fail in
patients with very high uric

114
00:06:43,840 --> 00:06:47,080
acid levels.
PRX 115 is designed to help

115
00:06:47,080 --> 00:06:49,760
breakdown uric acid where
standard therapies can't.

116
00:06:49,840 --> 00:06:53,320
It's a high need, high margin
target with phase two trials set

117
00:06:53,320 --> 00:06:57,360
to begin in late 2025.
And while that's cooking,

118
00:06:57,440 --> 00:07:02,320
there's PRX 19 tastes, still
preclinical but built the target

119
00:07:02,320 --> 00:07:05,920
diseases associated with
neutrophil extracellular traps,

120
00:07:05,960 --> 00:07:09,600
or Nets.
These are tangled webs of DNA

121
00:07:09,600 --> 00:07:12,560
and proteins released by white
blood cells, and they're

122
00:07:12,560 --> 00:07:16,320
implicated in a wide range of
inflammatory and autoimmune

123
00:07:16,320 --> 00:07:19,200
diseases.
If the platform works here, the

124
00:07:19,200 --> 00:07:21,000
addressable market could
explode.

125
00:07:21,240 --> 00:07:23,160
So what does that mean for
investors?

126
00:07:23,480 --> 00:07:26,840
This isn't A1 shot company.
It's a platform with real world

127
00:07:26,840 --> 00:07:29,800
validation. 1 drug
commercialized via Pfizer,

128
00:07:29,920 --> 00:07:33,160
another scaling through cheesy,
and two more in the pipeline.

129
00:07:33,640 --> 00:07:36,080
It's the kind of structure you
usually see in billion dollar

130
00:07:36,080 --> 00:07:39,280
biotechs, not micro caps under
$200 million.

131
00:07:39,440 --> 00:07:41,720
And here's the punchline.
The market still thinks of

132
00:07:41,720 --> 00:07:44,960
Protolix as a science project,
but the company is already

133
00:07:44,960 --> 00:07:48,600
generating revenue, already
producing its scale, and already

134
00:07:48,600 --> 00:07:51,840
improving treatment options and
rare diseases where every

135
00:07:51,840 --> 00:07:55,360
percent of clinical improvement
can justify thousands of dollars

136
00:07:55,360 --> 00:07:58,320
in pricing power.
In Segment 3, we break down the

137
00:07:58,320 --> 00:08:01,320
numbers because once you
understand the financials, the

138
00:08:01,320 --> 00:08:05,080
revenue, the earnings beat and
the price targets, this story

139
00:08:05,080 --> 00:08:08,480
gets even more compelling.
Let's talk numbers, because this

140
00:08:08,480 --> 00:08:12,360
isn't a biotech that's burning
through cash praying for Phase 3

141
00:08:12,360 --> 00:08:14,840
results.
This is a company that's already

142
00:08:14,840 --> 00:08:17,920
profitable.
In 2024, Prodelix generated

143
00:08:17,920 --> 00:08:23,400
$53.4 million in revenue, up 31%
from the year before.

144
00:08:23,640 --> 00:08:27,480
And what about net income, $18.9
million?

145
00:08:27,640 --> 00:08:31,080
That's right, this small cap
plant based biotech actually

146
00:08:31,080 --> 00:08:34,360
makes money.
Most biotech stocks under $3 are

147
00:08:34,360 --> 00:08:38,919
in phase one or Phase 2 with no
revenue, no product and constant

148
00:08:38,919 --> 00:08:41,799
dilution risk.
But Protolix is on a different

149
00:08:41,799 --> 00:08:43,919
track.
The company has no long term

150
00:08:43,919 --> 00:08:47,200
debt, no toxic warrants.
It cleaned up its balance sheet

151
00:08:47,200 --> 00:08:51,800
in 2024, retired its convertible
notes and now operates from a

152
00:08:51,800 --> 00:08:56,040
position of strength with $34.8
million in cash.

153
00:08:56,240 --> 00:08:59,520
That's why this episode exists,
because the market hasn't caught

154
00:08:59,520 --> 00:09:03,120
up.
PLX trades at around $2.48 as of

155
00:09:03,120 --> 00:09:07,800
March 26th, 2025, but with $0.32
of projected earnings for this

156
00:09:07,800 --> 00:09:11,920
year, the stock is trading at a
forward PE ratio of just 7.8.

157
00:09:12,320 --> 00:09:14,960
That's not biotech pricing,
that's deep value.

158
00:09:15,120 --> 00:09:17,840
And that forward earnings
estimate isn't fluff.

159
00:09:18,160 --> 00:09:21,680
It's built on royalty income
from Alaso, commercial momentum

160
00:09:21,680 --> 00:09:24,360
from a Fabrio and tight expense
management.

161
00:09:25,040 --> 00:09:27,760
What's more, analysts expect
that earnings could grow to

162
00:09:27,800 --> 00:09:32,400
$0.84 by 2026.
At a reasonable 15 pipe E, that

163
00:09:32,400 --> 00:09:36,320
would put the stock around
$12.60 and that's before

164
00:09:36,320 --> 00:09:39,480
factoring in pipeline success.
But let's get tactical.

165
00:09:39,720 --> 00:09:42,240
We're sending a 12 month price
target of $6.

166
00:09:42,520 --> 00:09:46,000
That's a clean, credible jump
from today's $2.48.

167
00:09:46,280 --> 00:09:49,520
A move like that would deliver a
140% return.

168
00:09:49,880 --> 00:09:54,000
And on the downside, support
sits near $1.80.

169
00:09:54,480 --> 00:09:57,040
That's about a 30% drawdown if
something goes wrong.

170
00:09:57,200 --> 00:10:00,760
That gives you a risk reward
ratio of roughly 4 to one.

171
00:10:01,160 --> 00:10:04,880
In other words, for every dollar
you risk, you could make 4.

172
00:10:05,280 --> 00:10:08,640
That's the kind of asymmetry
most traders dream of, and it's

173
00:10:08,640 --> 00:10:10,840
hiding in plain sight.
And a company with real

174
00:10:10,840 --> 00:10:14,280
products, clean books and upside
built into the fundamentals.

175
00:10:14,480 --> 00:10:19,440
Now let's zoom out five years.
A full product ramp on El Fabrio

176
00:10:19,760 --> 00:10:25,600
PRX 115 successfully through
Phase 2, a licensing deal on PRX

177
00:10:25,600 --> 00:10:28,840
119.
Add in modest pipeline success,

178
00:10:28,920 --> 00:10:32,640
market expansion and earnings
growth, and we believe PLX can

179
00:10:32,640 --> 00:10:35,640
hit $20.
That's your 8X scenario.

180
00:10:35,880 --> 00:10:40,240
And the beauty is it doesn't
take biotech mania to get there.

181
00:10:40,760 --> 00:10:44,840
No mean stock fever, no Reddit
driven rallies, just continued

182
00:10:44,840 --> 00:10:49,160
execution, market re rating, and
a platform that scales the

183
00:10:49,160 --> 00:10:51,960
current valuation under $200
million.

184
00:10:52,560 --> 00:10:56,280
The opportunity much bigger.
So why hasn't Wall Street caught

185
00:10:56,280 --> 00:10:58,160
on?
Part of it is geography.

186
00:10:58,360 --> 00:11:01,520
Protolix is based in Israel, not
Boston or San Diego.

187
00:11:02,080 --> 00:11:05,240
Part of it is bias.
Plant cell biologics still feel

188
00:11:05,240 --> 00:11:07,560
unfamiliar to many institutional
investors.

189
00:11:07,960 --> 00:11:11,440
And part of it is just inertia.
The company cleaned up its

190
00:11:11,440 --> 00:11:14,280
capital structure.
Quietly, it got profitable.

191
00:11:14,280 --> 00:11:16,560
Quietly, it's moving up.
Quietly.

192
00:11:16,720 --> 00:11:20,120
But that's where we thrive.
We don't chase the noise.

193
00:11:20,240 --> 00:11:23,720
We track the signal.
And when a company this clean,

194
00:11:23,880 --> 00:11:27,360
this overlooked and this
leverage shows up on our radar,

195
00:11:27,520 --> 00:11:30,280
we lean in.
Coming up next, what gives

196
00:11:30,280 --> 00:11:33,680
Protolix its edge?
We break down The X Factor, the

197
00:11:33,680 --> 00:11:37,160
platform, the mote, and the
biotech mechanics that Wall

198
00:11:37,160 --> 00:11:40,120
Street's missing.
Every breakout company has an X

199
00:11:40,120 --> 00:11:43,240
Factor, the thing that makes it
different, durable and

200
00:11:43,240 --> 00:11:46,120
defensible.
For Protolix, that edge is the

201
00:11:46,120 --> 00:11:49,400
platform.
It's called Procell X and it's

202
00:11:49,400 --> 00:11:51,840
not an experiment.
It's a working, revenue

203
00:11:51,920 --> 00:11:55,360
regenerating, FDA approved bio
manufacturing system that just

204
00:11:55,360 --> 00:11:57,360
doesn't look like anything else
in biotech.

205
00:11:57,560 --> 00:12:02,120
Most biologic drugs, the complex
ones used to treat cancers, rare

206
00:12:02,120 --> 00:12:05,160
diseases and autoimmune
disorders, are produced in

207
00:12:05,160 --> 00:12:07,880
hamster, ovary cells or
bacterial cultures.

208
00:12:08,400 --> 00:12:11,880
These systems require massive
bioreactors, extensive

209
00:12:11,880 --> 00:12:14,760
filtration and tightly
controlled environments to

210
00:12:14,760 --> 00:12:18,920
prevent viral contamination.
It's expensive, fragile, and

211
00:12:18,920 --> 00:12:21,720
industrial in every sense.
Rotelix said.

212
00:12:22,000 --> 00:12:23,400
What if we didn't need any of
that?

213
00:12:23,760 --> 00:12:26,720
What if we could grow these
proteins in plant cells and

214
00:12:26,720 --> 00:12:30,680
carrot cells specifically inside
sterile, scalable bioreactors?

215
00:12:31,040 --> 00:12:34,520
That's what Procell X is, a
plant based expression platform

216
00:12:34,520 --> 00:12:38,080
that simplifies production,
slashes contamination risk and

217
00:12:38,080 --> 00:12:40,200
dramatically lowers the cost of
goods sold.

218
00:12:40,400 --> 00:12:45,360
This is biotech as it was meant
to be flexible, efficient and

219
00:12:45,360 --> 00:12:48,000
modular.
The platform has already

220
00:12:48,000 --> 00:12:52,960
produced 2 approved drugs in a
kicker, those drugs didn't just

221
00:12:52,960 --> 00:12:56,800
work, they passed through the
FDA using this exact production

222
00:12:56,800 --> 00:12:58,840
method.
That's not just proof of

223
00:12:58,840 --> 00:13:02,280
concept, that's validation at
the highest level.

224
00:13:02,400 --> 00:13:06,240
And unlike other platforms,
Procel X has repeatability.

225
00:13:06,680 --> 00:13:09,120
You're not reinventing the
process for every molecule.

226
00:13:09,680 --> 00:13:12,480
Once the system is tuned, it can
be applied across multiple

227
00:13:12,480 --> 00:13:14,800
proteins.
That's how Protolix went from a

228
00:13:14,800 --> 00:13:20,120
lasso to El Fabrio and now
toward PRX 115 and PRX 119.

229
00:13:20,600 --> 00:13:23,520
The production system is the
engine, not just the lab.

230
00:13:23,720 --> 00:13:25,840
But here's where it gets even
more compelling.

231
00:13:26,080 --> 00:13:28,320
Protolix isn't just a tech
innovator.

232
00:13:28,400 --> 00:13:31,160
It's a company that's already
survived the hardest part of

233
00:13:31,160 --> 00:13:33,440
biotech.
They've already cleared the debt

234
00:13:33,440 --> 00:13:35,600
trap.
They've already de risked

235
00:13:35,600 --> 00:13:38,040
dilution.
There are no toxic warrants

236
00:13:38,040 --> 00:13:41,520
hanging over the stock, no
billion dollar liabilities on

237
00:13:41,520 --> 00:13:43,520
the books.
They're clean, they're

238
00:13:43,520 --> 00:13:46,760
profitable, and they're focused.
And that creates optionality.

239
00:13:47,120 --> 00:13:50,720
Without debt covenants or cash
burn pressure, Protolix can make

240
00:13:50,720 --> 00:13:54,160
long term decisions.
They can scale PRX 102 without

241
00:13:54,160 --> 00:13:57,600
cutting their R&D pipeline.
They can negotiate licensing

242
00:13:57,600 --> 00:14:00,240
deals from a position of
strength, not desperation.

243
00:14:00,760 --> 00:14:03,480
That's rare in biotech,
especially at this market cap.

244
00:14:03,720 --> 00:14:08,280
And let's not overlook the IP.
The Procell X system isn't open

245
00:14:08,280 --> 00:14:10,080
source.
It's proprietary.

246
00:14:10,400 --> 00:14:13,520
The company holds dozens of
patents around the expression

247
00:14:13,520 --> 00:14:17,360
system, bioreactor design and
downstream processing.

248
00:14:17,920 --> 00:14:20,640
That means if another biotech
wants to replicate this

249
00:14:20,640 --> 00:14:23,160
approach, they'll have to pay
for partner.

250
00:14:23,280 --> 00:14:27,480
And in an era where supply
chains, contamination risks and

251
00:14:27,480 --> 00:14:31,280
cost per dose all matter more
than ever, a clean, plant based

252
00:14:31,280 --> 00:14:34,920
platform that works at scale
isn't just a novelty, it's a

253
00:14:34,920 --> 00:14:37,280
Moat.
When Big Pharma starts looking

254
00:14:37,280 --> 00:14:40,640
for M&A targets that improve
manufacturing margins, Protolix

255
00:14:40,640 --> 00:14:42,440
starts looking like a strategic
asset.

256
00:14:42,600 --> 00:14:46,040
This isn't a story about science
experiments in clinical hope.

257
00:14:46,480 --> 00:14:49,120
This is a story about
infrastructure, biotech

258
00:14:49,120 --> 00:14:52,160
infrastructure that's been
built, validated, and priced

259
00:14:52,160 --> 00:14:55,520
like it doesn't exist.
That's the disconnect and that's

260
00:14:55,520 --> 00:14:58,560
the edge.
Coming up in Segment 5, Why now?

261
00:14:59,040 --> 00:15:01,560
Why biotech?
Why rare diseases?

262
00:15:01,840 --> 00:15:05,160
We zoom out and explain why this
entire space could be about to

263
00:15:05,160 --> 00:15:08,480
reprice and how Protolix is
perfectly positioned to ride the

264
00:15:08,480 --> 00:15:12,120
next sector wave.
Biotech is back for real.

265
00:15:13,000 --> 00:15:16,640
After two years of rate hikes,
broken balance sheets and VC

266
00:15:16,640 --> 00:15:20,960
pull back, the Fed has pivoted,
liquidity is returning, risk on

267
00:15:20,960 --> 00:15:25,120
capital is back in motion, and
biotech, the most asymmetric,

268
00:15:25,120 --> 00:15:28,520
misunderstood and momentum
driven sector in the market, is

269
00:15:28,520 --> 00:15:30,760
waking up.
And we've seen this story

270
00:15:30,760 --> 00:15:33,720
before.
Biotech always comes back in

271
00:15:33,720 --> 00:15:36,160
waves.
It happened after the 2008

272
00:15:36,160 --> 00:15:38,240
crash.
It happened again after the

273
00:15:38,240 --> 00:15:41,440
COVID tech rush.
Every time macro pressure fades

274
00:15:41,440 --> 00:15:45,160
and capital returns to growth,
biotech rebounds faster and

275
00:15:45,160 --> 00:15:47,520
harder than almost any other
sector.

276
00:15:47,960 --> 00:15:50,720
And this time, it's rare disease
that's leading the charge.

277
00:15:50,920 --> 00:15:54,120
Rare diseases aren't just
morally compelling, they're

278
00:15:54,120 --> 00:15:57,040
financially strategic.
These are high priority

279
00:15:57,040 --> 00:16:00,400
conditions with small patient
populations, massive unmet

280
00:16:00,400 --> 00:16:04,080
needs, and limited competition.
From an investment standpoint,

281
00:16:04,160 --> 00:16:07,560
it's the perfect setup.
Fewer rivals, faster FDA

282
00:16:07,560 --> 00:16:10,000
pathways and ultra high pricing
power.

283
00:16:10,160 --> 00:16:13,920
And the data backs it up.
Over the past five years, orphan

284
00:16:13,920 --> 00:16:17,160
drugs have outperformed
traditional pharma by more than

285
00:16:17,160 --> 00:16:20,240
two to one in pricing power and
profitability.

286
00:16:20,760 --> 00:16:23,040
Why?
Because rare disease patients

287
00:16:23,120 --> 00:16:26,000
often require lifelong
treatment, and insurance

288
00:16:26,000 --> 00:16:29,160
companies pay because there's no
alternative.

289
00:16:29,400 --> 00:16:31,960
And to that, the regulatory
tailwinds.

290
00:16:32,200 --> 00:16:35,960
The Orphan Drug Act of 1983 gave
drug makers a full suite of

291
00:16:35,960 --> 00:16:38,360
advantages.
Tax credits, seven years of

292
00:16:38,360 --> 00:16:42,800
market exclusivity, reduced fees
and expedited review timelines.

293
00:16:43,280 --> 00:16:46,840
That's why Big Pharma keeps
buying small companies with even

294
00:16:46,880 --> 00:16:50,640
early stage orphan assets.
It's not just about science,

295
00:16:50,800 --> 00:16:53,760
it's about structure.
And that brings us back to

296
00:16:53,760 --> 00:16:57,480
Protolix, because PLX checks
every box.

297
00:16:57,920 --> 00:16:59,680
They're not just a rare disease
player.

298
00:16:59,720 --> 00:17:02,640
They're a rare disease player
with actual revenue, actual

299
00:17:02,640 --> 00:17:05,160
products, and a proven
manufacturing platform.

300
00:17:05,599 --> 00:17:09,520
No fairy dust #2029 pipeline
dreams, Just commercial

301
00:17:09,520 --> 00:17:13,280
execution and clean economics.
And the big guys are watching

302
00:17:13,720 --> 00:17:16,880
M&A activity and rare disease is
picking back up.

303
00:17:17,440 --> 00:17:22,000
In Q1 of this year alone, more
than $40 billion in biotech

304
00:17:22,000 --> 00:17:23,640
acquisitions have been
announced.

305
00:17:24,240 --> 00:17:29,640
Sanofi, Tekeda, AstraZeneca.
Everyone wants pipeline,

306
00:17:30,200 --> 00:17:34,200
everyone wants profitability,
and everyone wants the next

307
00:17:34,200 --> 00:17:37,520
orphan platform that can scale.
Protolex won't stay under the

308
00:17:37,520 --> 00:17:42,920
radar forever if El Fabrio
continues to expand, if PRX 115

309
00:17:43,080 --> 00:17:46,960
hits its phase two milestones,
if Procelex gets wider traction

310
00:17:46,960 --> 00:17:50,280
across the industry, this
company will get re rated either

311
00:17:50,280 --> 00:17:53,400
through institutional buying or
through strategic interest.

312
00:17:53,920 --> 00:17:58,080
Either way, upside accelerates.
And the timing matters.

313
00:17:58,560 --> 00:18:01,440
Investors forget that all upside
is relative.

314
00:18:01,760 --> 00:18:05,040
If you buy when the sector is
already hot, the easy money is

315
00:18:05,040 --> 00:18:07,520
gone.
But if you enter just before

316
00:18:07,520 --> 00:18:09,400
cinnamon shifts, you catch the
wave.

317
00:18:10,000 --> 00:18:13,160
Cordelix isn't just a stock,
it's a timing opportunity.

318
00:18:13,280 --> 00:18:17,760
It's also worth comparing PLX to
past rare disease comebacks.

319
00:18:18,280 --> 00:18:23,400
Alnylam traded under $10 before
it's RNAI engine caught fire,

320
00:18:23,920 --> 00:18:28,320
Biomarin took years before Wall
Street paid attention and even

321
00:18:28,320 --> 00:18:31,400
Moderna long before COVID was
viewed as a long shot.

322
00:18:31,880 --> 00:18:36,080
But platforms win in the long
run, and Protolix has a platform

323
00:18:36,080 --> 00:18:38,400
and.
Now the macro is finally

324
00:18:38,400 --> 00:18:44,680
aligned, biotechs on sale, rare
disease is back in focus, the

325
00:18:44,680 --> 00:18:48,200
Fed is done hiking, and the
market is rotating toward

326
00:18:48,200 --> 00:18:51,680
profitability with growth.
Mortality sits right at that

327
00:18:51,680 --> 00:18:54,440
intersection.
Coming up in Segment 6, every

328
00:18:54,440 --> 00:18:57,600
opportunity has risks.
We'll walk through the clinical,

329
00:18:57,600 --> 00:19:01,200
commercial, and volatility
concerns and explain why, even

330
00:19:01,200 --> 00:19:03,880
with those in mind, the 8X case
still holds.

331
00:19:04,040 --> 00:19:07,440
Let's be real, no stock 8X is
without risk.

332
00:19:07,760 --> 00:19:11,640
And PLX, like every biotech, has
its vulnerabilities.

333
00:19:12,200 --> 00:19:15,720
Clinical timelines can slip,
regulatory approvals can get

334
00:19:15,720 --> 00:19:18,640
delayed.
Commercial ramp UPS rarely move

335
00:19:18,640 --> 00:19:21,120
in straight lines.
And even with two approved

336
00:19:21,120 --> 00:19:24,880
products, Protolix still has to
prove it can scale both sales

337
00:19:24,880 --> 00:19:27,320
and science.
This is biotech.

338
00:19:27,520 --> 00:19:29,960
It moves fast and it breaks
often.

339
00:19:30,360 --> 00:19:35,400
Start with TRX 1O2L Fabrio.
Yes, it's approved, but

340
00:19:35,400 --> 00:19:38,280
commercialization and rare
diseases is complex.

341
00:19:38,640 --> 00:19:40,360
It's not just about having a
product.

342
00:19:40,560 --> 00:19:43,480
It's about market access, pair
coverage, specialist

343
00:19:43,480 --> 00:19:45,800
relationships and physician
adoption.

344
00:19:46,280 --> 00:19:48,840
Fabri disease already has
established players like

345
00:19:48,840 --> 00:19:52,520
Fabrizime and Gallifold.
El Fabrio needs to show not just

346
00:19:52,520 --> 00:19:55,840
equivalency, but superiority, or
at least meaningful

347
00:19:55,840 --> 00:19:59,200
differentiation.
Otherwise, doctors won't switch.

348
00:19:59,360 --> 00:20:01,480
And we have to factor in pricing
pressure.

349
00:20:02,120 --> 00:20:05,160
Even in rare disease, regulatory
bodies and payers are watching

350
00:20:05,160 --> 00:20:08,480
drug costs closely.
If El Fabrio doesn't deliver

351
00:20:08,480 --> 00:20:11,640
real world outcomes that align
with its price, Protolix could

352
00:20:11,640 --> 00:20:14,680
face resistance from insurers or
be forced into discounting.

353
00:20:15,040 --> 00:20:18,520
That could dent margins, slow
growth or shift capital away

354
00:20:18,520 --> 00:20:22,400
from pipeline development.
Then there's PRX 115, the gout

355
00:20:22,400 --> 00:20:24,960
program.
It hasn't entered Phase 2 yet.

356
00:20:25,280 --> 00:20:28,600
Trial delays, patient enrollment
challenges or suboptimal

357
00:20:28,600 --> 00:20:32,200
efficacy could derail momentum,
and the market Protolix is

358
00:20:32,200 --> 00:20:36,480
entering isn't empty horizons.
Chris Dexa already dominates the

359
00:20:36,480 --> 00:20:40,360
uncontrolled gout space, and new
entrants are watching closely.

360
00:20:40,800 --> 00:20:43,760
To carve out a niche, Protolix
will need not just clinical

361
00:20:43,760 --> 00:20:46,840
success, but differentiation and
positioning.

362
00:20:47,080 --> 00:20:50,200
And here's a real world risk.
Protolix is a small company.

363
00:20:50,400 --> 00:20:54,720
They have 100 employees.
They don't have a massive sales

364
00:20:54,720 --> 00:20:58,480
force, so their ability to scale
revenue depends heavily on their

365
00:20:58,480 --> 00:21:01,680
partners.
Pfizer for El Alaso and Cheesy

366
00:21:01,680 --> 00:21:04,880
for El Fabrio.
If either of those relationships

367
00:21:04,880 --> 00:21:09,680
breakdown or if partner
execution lags, PLX takes the

368
00:21:09,680 --> 00:21:11,480
hit.
The Procel X platform is

369
00:21:11,480 --> 00:21:14,240
validated yes, but still
unconventional.

370
00:21:14,760 --> 00:21:17,480
Plant based biologics are not
the industry norm.

371
00:21:17,960 --> 00:21:20,920
If production issues arise,
batch variability, yield

372
00:21:20,920 --> 00:21:24,000
efficiency, purification
problems, then investors might

373
00:21:24,000 --> 00:21:26,120
start to question the
scalability of the model.

374
00:21:26,480 --> 00:21:29,360
That could cut the stocks upside
even if the science remains

375
00:21:29,360 --> 00:21:31,560
strong.
And let's talk volatility.

376
00:21:32,000 --> 00:21:34,760
PLX trades with a daily range of
6%.

377
00:21:35,160 --> 00:21:39,680
That means this stock can move
15 to 20% in either direction

378
00:21:39,680 --> 00:21:43,280
based on headlines, sector
sentiment or one analyst note.

379
00:21:43,560 --> 00:21:46,800
It's a liquid, it's emotional
and it's not for investors who

380
00:21:46,800 --> 00:21:49,320
panic on red candles.
But that's where we flip the

381
00:21:49,320 --> 00:21:54,200
lens because PLX is also rare.
It's a profitable biotech, under

382
00:21:54,200 --> 00:21:57,840
$200 million in market cap.
It has no debt.

383
00:21:58,160 --> 00:22:00,080
It retired its convertible
notes.

384
00:22:00,440 --> 00:22:03,560
It has cash in the bank and a
clean share structure.

385
00:22:04,000 --> 00:22:07,720
That's not typical, that's
strategic, and it's exactly the

386
00:22:07,720 --> 00:22:10,880
kind of setup Smart Capital
looks for when the biotech cycle

387
00:22:10,880 --> 00:22:13,440
turns.
The risk reward is just hard to

388
00:22:13,440 --> 00:22:16,160
ignore.
You're risking a 20 to 30%

389
00:22:16,160 --> 00:22:21,320
downside if execution slips, but
you're chasing a 140% gain in

390
00:22:21,320 --> 00:22:25,160
the next 12 months and an 8X
upside if the long term thesis

391
00:22:25,160 --> 00:22:27,600
plays out.
The market isn't pricing the

392
00:22:27,600 --> 00:22:30,120
cash flows, the platform or the
pipeline.

393
00:22:30,600 --> 00:22:33,600
It's pricing the uncertainty and
that's the opportunity.

394
00:22:33,800 --> 00:22:37,160
And here's the big idea.
This isn't about chasing hype.

395
00:22:37,600 --> 00:22:39,280
It's about catching this
pricing.

396
00:22:39,640 --> 00:22:42,320
Biotech is hard, but platforms
win.

397
00:22:42,840 --> 00:22:46,480
Protolix has a working one
products in market and a

398
00:22:46,480 --> 00:22:50,480
pipeline that fits the moment.
If you missed Moderna in 2018,

399
00:22:50,640 --> 00:22:53,960
If you missed Biomeron or Al
Nylum, PLX could be your next

400
00:22:53,960 --> 00:22:56,440
chance to catch the wave before
Wall Street recalibrates.

401
00:22:56,600 --> 00:23:00,200
Coming up next, Your Playbook,
we'll break down seven ways to

402
00:23:00,200 --> 00:23:04,440
play PLX, from tactical trading
to long term conviction, and how

403
00:23:04,440 --> 00:23:07,880
to position around one of the
most overlooked biotech stories

404
00:23:07,880 --> 00:23:10,520
of the year.
Let's shift from strategy to

405
00:23:10,520 --> 00:23:12,440
action.
You've heard the science.

406
00:23:12,720 --> 00:23:15,160
You've seen the numbers, now
here's your playbook.

407
00:23:15,360 --> 00:23:18,200
Seven ways to make money from
PLX, depending on your skill

408
00:23:18,200 --> 00:23:20,720
set, time horizon, and risk
appetite.

409
00:23:20,880 --> 00:23:23,840
Number one swing trade the
catalysts.

410
00:23:24,160 --> 00:23:28,640
PLX has earnings volatility
baked in Last quarter, the stock

411
00:23:28,640 --> 00:23:32,360
jumped 42% in two days after a
surprise beat.

412
00:23:32,720 --> 00:23:35,400
You don't have to marry the
position, just catch the moves

413
00:23:35,400 --> 00:23:39,400
around earnings, clinical trial
updates and regulatory events.

414
00:23:39,800 --> 00:23:44,480
This name doesn't drift.
It's Surgis. #2 build a rare

415
00:23:44,480 --> 00:23:48,400
disease biotech newsletter.
If you're a researcher, creator,

416
00:23:48,400 --> 00:23:51,680
or investor, there's massive
value in curating insights

417
00:23:51,680 --> 00:23:55,600
around orphan drug development.
PLX is your starting point, but

418
00:23:55,600 --> 00:23:57,200
the whole sector is under
covered.

419
00:23:57,520 --> 00:23:59,680
You can monetize through
subscriptions, industry

420
00:23:59,680 --> 00:24:03,920
partnerships, or even Angel deal
flow leads. #3 bet on the

421
00:24:03,920 --> 00:24:08,560
broader biotech platform trend.
PLX is part of a deeper wave

422
00:24:08,560 --> 00:24:12,840
synthetic biology, plant based
biologics, cell free protein

423
00:24:12,840 --> 00:24:16,160
manufacturing.
If PLX wins, it could send

424
00:24:16,160 --> 00:24:20,280
signal across ETFs like ARC or
send biospecific funds.

425
00:24:20,640 --> 00:24:23,360
You're not just playing one
company, you're front running a

426
00:24:23,360 --> 00:24:27,040
macro thesis. #4 short
competitors.

427
00:24:27,080 --> 00:24:30,560
Strategically, if Elfabrio
expands market share, it could

428
00:24:30,560 --> 00:24:33,560
pressure names like Amicus,
Santa Fe or Horizon.

429
00:24:33,920 --> 00:24:38,880
If PRX 115 delivers delt players
like Takeda or T Gene could feel

430
00:24:38,880 --> 00:24:42,960
the margin heat Long PLX short
overexposed incumbents.

431
00:24:43,360 --> 00:24:48,560
That's how you create biotech
pairs trades. #5 Build APLX

432
00:24:48,640 --> 00:24:52,080
Catalyst calendar.
This company is event driven.

433
00:24:52,400 --> 00:24:57,120
Key triggers ahead include PRX
100 and Fifteens phase two trial

434
00:24:57,120 --> 00:25:01,040
quarterly earnings and PRX 1O2
label expansion updates.

435
00:25:01,520 --> 00:25:06,040
Track those dates, create watch
lists and trade expectations,

436
00:25:06,160 --> 00:25:09,600
not just outcomes.
That's how real biotech money is

437
00:25:09,600 --> 00:25:12,120
made.
Number six, invest in early

438
00:25:12,120 --> 00:25:14,800
stage biotech startups through
crowdfunding platforms.

439
00:25:15,160 --> 00:25:18,200
PLX is the validation that
overlooked platforms can

440
00:25:18,200 --> 00:25:20,760
breakthrough.
Now imagine spotting the next

441
00:25:20,760 --> 00:25:22,840
protolix before the rest of the
world does.

442
00:25:23,200 --> 00:25:26,080
Sites like Bioverge and We
Funder make that possible.

443
00:25:26,520 --> 00:25:29,360
Just know the risk curve is
higher, but so is the return

444
00:25:29,360 --> 00:25:34,400
potential. #7 Trade PLX is
volatility with options.

445
00:25:34,760 --> 00:25:39,280
This stock moves 6% daily range
on average on red days.

446
00:25:39,280 --> 00:25:43,000
Some traders sell puts, like
selling insurance on a stock

447
00:25:43,000 --> 00:25:46,520
they already want to own.
You collect premium, benefit

448
00:25:46,520 --> 00:25:49,600
from time decay, and get
assigned shares only if the

449
00:25:49,600 --> 00:25:53,080
stock drops.
Others by calls lower risk

450
00:25:53,160 --> 00:25:56,000
leveraged upside.
But here's the real strategy.

451
00:25:56,000 --> 00:25:58,760
Build a core long position and
then trade around it.

452
00:25:59,200 --> 00:26:00,960
Add to your position on red
days.

453
00:26:01,280 --> 00:26:04,880
Trim into green spikes.
You stay along the trend but use

454
00:26:04,880 --> 00:26:08,560
the volatility to boost returns.
That's how pros manage small cap

455
00:26:08,560 --> 00:26:12,400
biotech risk.
And don't stop there, turn this

456
00:26:12,400 --> 00:26:15,280
into content.
Start a sub stock, build a

457
00:26:15,280 --> 00:26:19,600
biotech YouTube series, launch
APLX focused discord or small

458
00:26:19,600 --> 00:26:22,680
cap research group.
When you own the edge and you

459
00:26:22,680 --> 00:26:25,520
share it, you build influence
and income.

460
00:26:25,920 --> 00:26:29,760
The world doesn't reward passive
watching, it rewards leveraged

461
00:26:29,760 --> 00:26:32,360
action.
Pick your play and move on it,

462
00:26:32,880 --> 00:26:35,520
because conviction without
movement is just noise.

463
00:26:35,680 --> 00:26:39,760
Coming up in Segment 8, your
final takeaways, call to action

464
00:26:39,760 --> 00:26:42,360
and the legal wrap.
Let's close strong.

465
00:26:42,840 --> 00:26:45,560
If there's one thing we've
learned from past biotech

466
00:26:45,560 --> 00:26:48,320
cycles, it's this.
Platforms win.

467
00:26:48,720 --> 00:26:52,520
They take longer to build.
They don't always look flashy,

468
00:26:52,840 --> 00:26:56,560
but when they work, they work in
scale and protolix.

469
00:26:57,320 --> 00:27:01,440
It has a working platform, FDA
approved products and a pipeline

470
00:27:01,440 --> 00:27:05,880
built for precision.
PLX is trading at just $2.48.

471
00:27:06,280 --> 00:27:08,680
But the fundamentals say
something else.

472
00:27:09,160 --> 00:27:13,680
A company with revenue, with no
debt, with positive cash flow,

473
00:27:14,040 --> 00:27:17,200
with commercial stage drugs and
a pipeline that fits the macro

474
00:27:17,200 --> 00:27:19,720
trend.
That's not speculative, that's

475
00:27:19,720 --> 00:27:22,480
mispriced.
And that mispricing creates your

476
00:27:22,480 --> 00:27:25,040
edge.
Our 12 month target is 6

477
00:27:25,040 --> 00:27:30,680
dollars, 140% upside.
Our five year target is $20 and

478
00:27:30,680 --> 00:27:33,440
8X return.
Can things go wrong?

479
00:27:33,920 --> 00:27:36,520
Of course.
But with a risk reward ratio

480
00:27:36,520 --> 00:27:39,840
near 4 to one, the math works
and so does the story.

481
00:27:39,960 --> 00:27:42,880
So if you've been watching
biotech from the sidelines, this

482
00:27:42,880 --> 00:27:46,840
is your moment.
Biotech is back, rare disease is

483
00:27:46,840 --> 00:27:49,920
in, and Protolix sits right at
the intersection.

484
00:27:50,480 --> 00:27:53,000
The question is, will you wait
for Wall Street to tell you it's

485
00:27:53,000 --> 00:27:56,480
real, or will you move while
it's still quiet?

486
00:27:56,680 --> 00:28:00,680
Because this is where conviction
lives in the gaps between value

487
00:28:00,760 --> 00:28:05,560
and narrative, in the companies
that execute quietly, and in the

488
00:28:05,560 --> 00:28:08,240
investors who act before the
crowd shows up.

489
00:28:08,360 --> 00:28:11,080
If you want to stay ahead of
these global shifts, don't just

490
00:28:11,080 --> 00:28:15,160
listen, take action.
Subscribe now on Apple Podcasts

491
00:28:15,160 --> 00:28:17,520
and Spotify.
Follow us on Twitter for real

492
00:28:17,520 --> 00:28:30,080
time alerts and market threads
divedeeperwithourfulllineupfinance.frontieraifrontieraimakemoneyandmindsetfrontieraiallcuratedinoneplace@financefrontierai.com.

493
00:28:30,440 --> 00:28:33,120
And if you're already following
us, share this episode with a

494
00:28:33,120 --> 00:28:35,280
friend who actually invests with
strategy.

495
00:28:35,520 --> 00:28:38,400
And sign up for our newsletter
to get exclusive insights,

496
00:28:38,680 --> 00:28:41,960
breaking financial news and
expert analysis delivered

497
00:28:41,960 --> 00:28:44,480
straight to your inbox.
Now for the disclaimer.

498
00:28:44,560 --> 00:28:47,600
The information provided in this
episode is for informational

499
00:28:47,600 --> 00:28:50,400
purposes only.
Investing involves risk,

500
00:28:50,440 --> 00:28:52,480
including the potential loss of
capital.

501
00:28:52,960 --> 00:28:55,680
Always conduct your own due
diligence and consult with a

502
00:28:55,680 --> 00:28:58,600
licensed financial advisor
before making decisions.

503
00:28:58,720 --> 00:29:00,800
While we've highlighted
opportunities like Protofix

504
00:29:00,800 --> 00:29:05,280
Biotherapeutics ticker symbol
PLX, this episode does not

505
00:29:05,280 --> 00:29:07,720
provide personalized investment
advice.

506
00:29:08,240 --> 00:29:11,240
Past performance is not
indicative of future results and

507
00:29:11,240 --> 00:29:14,040
markets can change quickly.
We may hold positions and some

508
00:29:14,040 --> 00:29:17,440
of the companies discussed.
Transparency is important, so

509
00:29:17,440 --> 00:29:20,760
always verify information and
base your decisions on personal

510
00:29:20,760 --> 00:29:24,080
goals and risk tolerance.
The music in this episode is

511
00:29:24,080 --> 00:29:26,320
licensed under standard
agreements.

512
00:29:26,520 --> 00:29:29,920
Special thanks to Vibe Tracks
for the track Crystal provided

513
00:29:29,920 --> 00:29:32,560
under the YouTube Audio Library
license.

514
00:29:32,720 --> 00:29:37,680
This episode is copyright 2025
by Finance Frontier AI.

515
00:29:38,120 --> 00:29:41,120
All rights reserved.
Unauthorized reproduction or

516
00:29:41,120 --> 00:29:43,200
distribution is strictly
prohibited.

517
00:29:43,360 --> 00:29:47,480
Thanks for joining us today.
Stay strategic, stay focused and

518
00:29:47,480 --> 00:29:49,960
take action.
We'll see you next time.